Compare Amgen, Inc. (AMGN) vs Dell Technologies Inc (DELL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Dell Technologies Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Dell Technologies Inc trades at $429.5 (market cap $281.05B). The key difference: Dell Technologies Inc is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | DELL | |
|---|---|---|
Market Cap | $196.12B | $281.05B |
Sector | Health | Technology |
52-Week High | $388.16 | $466.02 |
52-Week Low | $271.18 | $111.10 |
Enterprise Value | $241.41B | $300.64B |
Dividend Yield | 2.77% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Dell Technologies stock trades at $435.05, down 3.37% over the past day, but maintains a bullish technical outlook with strong support near $436. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $4.86 significantly exceeding the $2.96 forecast. Revenue for 2025 reached $95.57 billion with a net income margin of 6.28%, showing improved profitability. Recent news highlights include positive analyst coverage and political endorsements driving investor interest.
The outlook for Dell remains positive with analyst consensus pointing to 12% upside to the $487.06 price target. Key opportunities include AI server demand growth and expanding profit margins, while risks involve PC industry headwinds and competitive pressures. The stock's current valuation at 34.66 P/E requires continued earnings growth to justify further appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Dell Technologies Inc
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →
